Literature DB >> 11046220

Neuroprotective effects of riluzole and ketamine during transient spinal cord ischemia in the rabbit.

J Lips1, P de Haan, P Bodewits, I Vanicky, M Dzoljic, M J Jacobs, C J Kalkman.   

Abstract

BACKGROUND: Massive release of central excitatory neurotransmitters is an important initial step in ischemic neuronal injury, and modification of this process may provide neuroprotection. We studied the protective effects of the voltage-dependent sodium channel antagonist riluzole and the N-methyl-d-aspartate receptor antagonist ketamine on hind limb motor function and histopathologic outcome in an experimental model of spinal cord ischemia.
METHODS: Temporary spinal cord ischemia was induced by 29 min of infrarenal balloon occlusion of the aorta in 60 anesthetized New Zealand white rabbits. Animals were randomly assigned to one of four treatment groups (n = 15 each): group C, saline (control); group R, riluzole, 8 mg/kg intravenously; group K, ketamine, 55 mg/kg intravenously; group RK, riluzole and ketamine. After reperfusion, riluzole treatment was continued with intraperitoneal infusions. Normothermia (38 degrees C) was maintained during ischemia, and rectal temperature was assessed before and after intraperitoneal infusions. Neurologic function, according to Tarlov's criteria, was evaluated every 24 h, and infarction volume and the number of eosinophilic neurons and viable motoneurons in the lumbosacral spinal cord was evaluated after 72 h.
RESULTS: Neurologic outcome was better in groups R and RK than in groups C and K. All animals in group C (100%) and all animals but one in group K (93%) were paraplegic 72 h after the ischemic insult versus 53% in group R and 67% in group RK (P < 0.01 each). More viable motoneurons were present in groups R and RK than in controls (P < 0.05).
CONCLUSIONS: The data indicate that treatment with riluzole can increase the tolerance of spinal cord motoneurons to a period of normothermic ischemia. Intraischemic ketamine did not provide neuroprotection in this model.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11046220     DOI: 10.1097/00000542-200011000-00025

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  9 in total

1.  Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival.

Authors:  Alice Y C Liu; Rohan Mathur; Newton Mei; Christopher G Langhammer; Bruce Babiarz; Bonnie L Firestein
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

Review 2.  Stronger is not always better: could a bodybuilding dietary supplement lead to ALS?

Authors:  Marin Manuel; C J Heckman
Journal:  Exp Neurol       Date:  2010-12-15       Impact factor: 5.330

Review 3.  Anaesthetic-related neuroprotection: intravenous or inhalational agents?

Authors:  Daniela Schifilliti; Giovanni Grasso; Alfredo Conti; Vincenzo Fodale
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

4.  Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury.

Authors:  J Marc Simard; Orest Tsymbalyuk; Kaspar Keledjian; Alexander Ivanov; Svetlana Ivanova; Volodymyr Gerzanich
Journal:  Exp Neurol       Date:  2011-12-08       Impact factor: 5.330

5.  Enhancing KCNQ Channel Activity Improves Neurobehavioral Recovery after Spinal Cord Injury.

Authors:  Zizhen Wu; Lin Li; Fuhua Xie; Guoying Xu; Danny Dang; Qing Yang
Journal:  J Pharmacol Exp Ther       Date:  2020-01-22       Impact factor: 4.030

6.  The Sur1-Trpm4 Channel in Spinal Cord Injury.

Authors:  J Marc Simard; Seung Kyoon Woo; Bizhan Aarabi; Volodymyr Gerzanich
Journal:  J Spine       Date:  2013-08-17

7.  Riluzole increases the amount of latent HSF1 for an amplified heat shock response and cytoprotection.

Authors:  Jingxian Yang; Kristen Bridges; Kuang Yu Chen; Alice Y-C Liu
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

Review 8.  The Impact of Riluzole on Neurobehavioral Outcomes in Preclinical Models of Traumatic and Nontraumatic Spinal Cord Injury: Results From a Systematic Review of the Literature.

Authors:  Lindsay A Tetreault; Mary P Zhu; Jefferson R Wilson; Spyridon K Karadimas; Michael G Fehlings
Journal:  Global Spine J       Date:  2019-05-12

9.  Riluzole Can Improve Sensory and Motor Function in Patients with Acute Spinal Cord Injury.

Authors:  Ali Meshkini; Firooz Salehpour; Javad Aghazadeh; Farhad Mirzaei; Seyed Ahmad Naseri Alavi
Journal:  Asian J Neurosurg       Date:  2018 Jul-Sep
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.